Login to Your Account



FDA Slaps Genzyme With Refuse to File for Lemtrada

By Catherine Shaffer
Staff Writer

Monday, August 27, 2012

The FDA surprised Genzyme Corp., a Sanofi company, with a refuse to file letter for its supplemental biologics license application (sBLA) for Lemtrada (alemtuzumab) as a treatment for relapsing multiple sclerosis (MS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription